MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Clinical trial NCT06534437 · RECRUITING

Trial details

NCT number: NCT06534437
Sponsor: Ryvu Therapeutics SA
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Hodgkin Lymphoma, B-cell

Start date: 2024-12-05
Primary completion: 2026-12-01
Enrollment: 178

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.